Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

<p>Supplemental Figure S6: In vivo efficacy of a range of doses of CLDN6-23-ADC in M202 xenograft models. ADC dosing is IV QW as indicated by the arrows</p>

Збережено в:
Бібліографічні деталі
Автор: Martina S.J. McDermott (15206951) (author)
Інші автори: Neil A. O'Brien (15206954) (author), Benjamin Hoffstrom (15206957) (author), KeWei Gong (15206960) (author), Ming Lu (15206963) (author), Jun Zhang (15206966) (author), Tong Luo (15206969) (author), Min Liang (15206972) (author), Weiping Jia (15206975) (author), Jenny J. Hong (15206978) (author), Kevin Chau (15206981) (author), Simon Davenport (15206984) (author), Bin Xie (15206987) (author), Michael F. Press (15206990) (author), Richard Panayiotou (15206993) (author), Abram Handly-Santana (15206996) (author), Joan S. Brugge (9710515) (author), Leonard Presta (15206999) (author), John Glaspy (15207002) (author), Dennis J. Slamon (15047067) (author)
Опубліковано: 2025
Предмети:
Cancer
Therapeutic Research and Development
Biological Agents & Therapies
Antibody-drug conjugates
Gynecological Cancers
Endometrial cancer
Ovarian cancer
Translational Research
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси